GENET-news
To stay informed you can subscribe to the GENET-news list.
2008-09-12 | permalink
Is the U.K. biotech industry on the skids?
If you listened to certain speakers at the recent ERBI ”Cambridge Biopartnering Exchange,” it would seem as if the glory days of U.K. biotech are over. Only Abcam, a Cambridge-based research antibody supply company, was held up as a example of how U.K. biotechs need to be to survive. So what’s wrong? [...] ”In 2007 and 2008, lots of U.K. biotechs didn’t deliver, and investors did not make a return, so VCs are increasingly moving away from early-stage companies.”
Overview
News
2008-09-12 | permalink
Is the U.K. biotech industry on the skids?
If you listened to certain speakers at the recent ERBI ”Cambridge Biopartnering Exchange,” it would seem as if the glory days of U.K. biotech are over. Only Abcam, a Cambridge-based research antibody supply company, was held up as a example of how U.K. biotechs need to be to survive. So what’s wrong? [...] ”In 2007 and 2008, lots of U.K. biotechs didn’t deliver, and investors did not make a return, so VCs are increasingly moving away from early-stage companies.”
GENET-news & GENET-forum
GENET-news is providing a daily news service on a range of topics regarding genetic engineering. We are screening the worldwide English news, press releases and other publications to provide you with a strategic selection of information. GENET-news enables you to stay informed about all aspects of the global controversy around GE technologies and GE organisms. You can subscribe by 
email.
The GENET-forum list provides you with additional background information and more voluminous reports. It is only open for GENET members. Please contact the coordinator for membership and subscription.